Intellia Therapeutics

Yahoo Finance • 5 days ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 7 days ago

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could revolutionize medicine by helping researcher... Full story

Yahoo Finance • 12 days ago

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Intellia Therapeutics, Inc. is positioned seventh on our list. TheFly reported on January 28 that Baird raised its price target on NTLA to $7 from $4 while ma... Full story

Yahoo Finance • 2 months ago

What Makes Intellia Therapeutics (NTLA) an Interesting Investment?

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% i... Full story

Yahoo Finance • 2 months ago

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Key Points A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges. 10 stocks we like better than Intell... Full story

Yahoo Finance • 2 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on Decembe... Full story

Yahoo Finance • 2 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood has been busy this week. The Ark Invest co-founder, CEO, and ace stock picker added to five of her existing growth stocks on Wednesday. I covered two of those names yesterday. Let's dive into the other three purchases. What's... Full story

Yahoo Finance • 3 months ago

Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones Trading dropped Intellia Therapeutics, Inc. (NASDAQ:NTLA) from Buy to Hold. The downgrade came after Intellia announ... Full story

Yahoo Finance • 3 months ago

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focu... Full story

Yahoo Finance • 3 months ago

Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price targ... Full story

Yahoo Finance • 3 months ago

Intellia cut to Peer Perform at Wolfe Research on Nex-z safety issues

[Wall Street New York stock exchange stock market] alexsl Intellia Therapeutics (NTLA [https://seekingalpha.com/symbol/NTLA]) downgraded to a Peer Perform rating from Outperform at Wolfe Reseach, primarily due to emerging safety concerns... Full story

Yahoo Finance • 3 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA... Full story

Yahoo Finance • 3 months ago

Cathie Wood's Ark Invest weekly moves: Adds to ACHR and CRSP, trims positions in ROKU and SOFI

[Wooden Blocks with ETF Letters Surrounded by Coins and Financial Icons Representing Investment Growth and Financial Strategies in a Modern Finance Context] Suphachai Panyacharoen Cathie Wood’s ARK Invest reshuffled its portfolio this wee... Full story

Yahoo Finance • 3 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for... Full story

Yahoo Finance • 4 months ago

Intellia hit with multiple downgrades following pause in phase 3 nex-z program

[Wall street district in New York City with USA flags in the background] FilippoBacci At least five Wall Street firms have downgraded their ratings on Intellia Therapeutics (NASDAQ:NTLA [https://seekingalpha.com/symbol/NTLA]) in the wake... Full story

Yahoo Finance • 4 months ago

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Argus upgraded Warner Bros. Discovery... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Increase Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the compan... Full story

Yahoo Finance • 4 months ago

Intellia (NTLA) Soars 13% to Fresh High

We recently published 10 Big Names Beating Wall Street at its Own Game. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best performers on Monday. Intellia Therapeutics soared to a new all-time high on Monday, despite the lack of... Full story

Yahoo Finance • 4 months ago

4 Healthcare Stocks to Buy Now

Key Points Two gene-editing companies are advancing therapies, with one generating commercial sales and both approaching major regulatory milestones. An AI drug discovery company is approaching multiple trial readouts in late 2025 that co... Full story